[Skip to Content]
[Skip to Content Landing]
Article
March 9, 1957

BETA, BETA-METHYLETHYLGLUTARIMIDE (MEGIMIDE) IN TREATMENT OF BARBITURATE INTOXICATIONREPORT OF A CASE

Author Affiliations

New York

From the Division of Anesthesiology, Memorial Center for Cancer and Allied Diseases.

JAMA. 1957;163(10):835-837. doi:10.1001/jama.1957.82970450001009
Abstract

In 1954, Shaw and co-workers1 introduced a new barbiturate antagonist, β,β-methylethylglutarimide (Megimide). Since then, many reports of its use for the treatment of barbiturate intoxication,2 activation of the electroencephalogram,3 and rapid termination of barbiturate anesthesia4 have appeared in the literature. The most satisfactory results have been obtained in patients who have taken less than 2 gm. of barbiturate and have been in coma for less than 12 hours. Because of the danger of overdosage (vomiting and muscular fasciculation), doses of 1 gm. of β,β-methylethylglutarimide have seldom been exceeded. This drug has been postulated to be either a barbiturate inactivator or a competitor for the same substrate in the brain.

The following case report is presented because of the use of a large dose of β,β-methylethylglutarimide (5.5 gm.) in the treatment of barbiturate intoxication. The electroencephalogram was employed to evaluate the depth of the narcosis and to

First Page Preview View Large
First page PDF preview
First page PDF preview
×